论文部分内容阅读
目的 了解平均粒径 53 6μm的白蛋白微球 (AMS)经颈外动脉灌注后 ,经动 -静脉短路 (AVA)溢出部分微球的量和在重要脏器的分布。方法 经家兔颈外动脉灌注1 2 5I标记的微球后抽取颈外静脉血 ,测定放射剂量和静脉血中所含微球的比例 ;观察微球经家兔颈外静脉推注后全身各重要脏器组织中微球的分布情况。结果 经颈外动脉注入微球后仅有 0 51 %的放射剂量出现在静脉血中。微球经静脉推注后 ,主要聚集于肺 ,其它各重要脏器未见分布。结论 以平均粒径 53 6μm的白蛋白微球作为口腔颌面部肿瘤栓塞化疗药物的载体 ,全身副作用轻微 ,是安全可行的
Objective To understand the amount of microspheres and the distribution in vital organs after AVA overflow through the external carotid artery (AMS) of 53μm in diameter. Methods Rabbit external carotid artery perfusion 125I-labeled microspheres after extraction of external jugular venous blood, radioimmunoassay and the proportion of microspheres contained in the venous blood were measured; microspheres were observed after injection of rabbit external jugular vein of the body The distribution of microspheres in vital organs. Results Only 0 51% of the radiation dose appeared in the venous blood after injecting the microspheres through the external carotid artery. Microspheres after intravenous bolus, the main accumulation in the lungs, other major organs were not distributed. Conclusion The albumin microspheres with an average particle size of 53 6 μm are the carriers of oral and maxillofacial tumor embolization chemotherapeutic drugs with mild systemic side effects and are safe and feasible